Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Amyotrophic Lateral Sclerosis Companies

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. While there is no cure for ALS, several pharmaceutical and biotechnology companies have been actively involved in research and development efforts to discover potential treatments for this debilitating condition.

Amyotrophic Lateral Sclerosis Key Companies.jpg Disclaimer: List of key companies in no particular order

Latest Amyotrophic lateral sclerosis Companies Update

October 2023: Phase II clinical trial of NLRP3 inhibitor "ZYIL1" in patients with Amyotrophic Lateral Sclerosis (ALS) has been approved by the Central Drugs Standard Control Organisation (CDSCO), Government of India. They believe that ZYIL1 will provide new avenues for treating ALS by reducing neuroinflammation and neurodegeneration. Neuroinflammation and fast neurodegeneration cause ALS sufferers to gradually lose the capacity to move, speak, eat, and breathe. Loss of motor neurons in the brain and spinal cord, which regulate voluntary muscle movement, is a hallmark of amyotrophic lateral sclerosis. Safety, tolerability, pharmacokinetics, and pharmacodynamics in ALS patients will be investigated in a Phase II clinical research. The main goal of this Phase 2 placebo-controlled, randomized, double-blind clinical study is the change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at Weeks 4, 8, and 12.

October 2023: In order to speed up the development of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS), BrainStorm Cell therapies Inc., a leading producer of adult stem cell therapies for neurodegenerative illnesses, has announced a strategic realignment. To further the development of treatments for amyotrophic lateral sclerosis (ALS), the company plans to 1) conduct a double-blind, placebo-controlled Phase 3b clinical trial for NurOwn in the United States with an open-label extension, and 2) maintain the publication of data from the Phase 3 clinical trial on biomarkers, long-term safety, and survival. However, the experiment did show a clinically relevant response in a pre-specified cohort of patients with less advanced illness, which may help explain why the ALSFRS-R scale had trouble measuring disease progression in individuals with severe ALS.

List of Amyotrophic lateral sclerosis Key companies in the market

Sun Pharmaceutical (India)

Mitsubishi Tanabe Pharma America (U.S.)

Biogen (UU.S)

Sanofi (France)

Mylan NN.V.(UU.S)

Covis Pharma (Switzerland)

Ionis Pharmaceutical (UU.S)

ITF Pharma (UU.S)

Ascend Pharmaceuticals LLC (UU.S)

Apotex Inc. (Canada)

Amyotrophic Lateral Sclerosis Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.